News

Risankizumab is being evaluated in immunological disorders, including Crohn's disease, psoriasis, psoriatic arthritis and asthma. Risankizumab is an investigational treatment that is part of a collaboration between Boehringer

Evotec announced the signing of a set of collaboration agreements with the life science business of Merck, which will combine Merck's portfolio of genome editing technologies with Evotec's versatile

PF-05280014 demonstrated equivalence in objective response rate to Herceptin after 25 weeks of treatment in first line patients with HER2-positive metastatic breast cancer. The Reflections B3271002 is a

The company's decision follows the start of phase 3 clinical trial of the Tetravalent Immunization against Dengue Efficacy Study (TIDES), the global phase 3 clinical trial to assess the efficacy of a

The expansion is in response to customer demand for medical device manufacturing, especially in the area of diabetes, and represents West's most recent investment in Ireland, where the

The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest, Sweden, in addition to current shareholders Kurma Partners, France,

Background to the acquisition This acquisition is consistent with Ergomed’s stated strategy to grow its existing, profitable services businesses both organically and through bolt-on acquisitions. The transaction will

As part of the agreement, Oxford BioMedica will develop and supply lentiviral vectors used by Orchard for the manufacture of ex-vivo gene therapy products in primary immune deficiency disorders and

Accucaps develops and manufactures over-the-counter (OTC), high potency and conventional pharmaceutical softgels. The companies did not disclose the financial details of the transaction, which is subject to approval from the Canadian